Your session is about to expire
← Back to Search
Nozin to Prevent Respiratory Infections in Stem Cell Transplant Patients
Phase 1
Waitlist Available
Led By Steven Pergam
Research Sponsored by Fred Hutchinson Cancer Research Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Undergoing allogeneic hematopoietic transplant for malignant or non-malignant disease
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 100 days post-transplant
Awards & highlights
Study Summary
This trial looks at the side effects of using Nozin to prevent respiratory viral infections in stem cell transplant patients. Nozin is a non-antibiotic, alcohol-based nasal sanitizer that may prevent community acquired respiratory virus infection in stem cell transplant recipients.
Who is the study for?
This trial is for English-speaking patients undergoing stem cell transplants for malignant or non-malignant diseases, who can consent and follow the study plan. They must be able to visit the transplant site for 100 days post-transplantation. Those with recent respiratory infections, using antiviral therapies, allergic to Nozin's ingredients, having nasal issues, on oxygen therapy or using daily nasal products cannot join.Check my eligibility
What is being tested?
The PREV-NOSE STUDY is testing Nozin's effectiveness in preventing respiratory viral infections during stem cell transplant recovery. It compares standard practices against the use of Nozin—a non-antibiotic nasal sanitizer—to see if it reduces infection rates.See study design
What are the potential side effects?
Potential side effects from Nozin may include irritation in the nose or an allergic reaction to its components like jojoba oil, orange oil, coconut oil, lauric acid, benzalkonium chloride or vitamin E.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am receiving a stem cell transplant from a donor.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 100 days post-transplant
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 100 days post-transplant
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of adverse events (AEs)
Tolerability of Nozin
Secondary outcome measures
Frequency of respiratory viral symptoms
Incidence of community acquired respiratory viruses (CARV)
Number of respiratory viral panel tests
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (Nozin)Experimental Treatment1 Intervention
Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the inside of their nose BID up to 100 days after transplant.
Group II: Arm II (standard of care)Active Control1 Intervention
Patients receive standard of care.
Find a Location
Who is running the clinical trial?
Fred Hutchinson Cancer Research CenterLead Sponsor
443 Previous Clinical Trials
148,195 Total Patients Enrolled
Global Life Technologies Corp.UNKNOWN
Fred Hutchinson Cancer CenterLead Sponsor
556 Previous Clinical Trials
1,343,218 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger